JB
Therapeutic Areas
PTC Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Translarna (ataluren) | Duchenne muscular dystrophy (nmDMD) | Marketed (Conditional) |
| Upstaza (eladocagene exuparvovec) | Aromatic L-amino acid decarboxylase (AADC) deficiency | Marketed |
| Evrysdi (risdiplam) | Spinal muscular atrophy (SMA) | Marketed |
| PTC518 | Huntington's disease | Phase 2 |
| Vatiquinone (EPI-743) | Friedreich's ataxia (FA) | Phase 3 |
| PTC923 (sepiapterin) | Phenylketonuria (PKU) | Phase 3 |
| PTC857 | Amyotrophic lateral sclerosis (ALS) / Neurological disorders | Preclinical/Phase 1 |
Leadership Team at PTC Therapeutics
MB
Matthew B. Klein
Chief Executive Officer
NA
Neil Almstead
Chief Technical Operations Officer
ME
Mark E. Boulding
Executive Vice President and Chief Legal Officer
LG
Lee Golden
Chief Medical Officer
PG
Pierre Gravier
Chief Financial Officer
MF
Mary Frances Harmon
Senior Vice President, Corporate and Patient Relations
LM
Linda Montella-Carter
Senior Vice President and Chief Information Officer
EP
Eric Pauwels
Chief Business Officer
HS
Hege Sollie-Zetlmayer
Chief Human Resources Officer